<DOC>
	<DOCNO>NCT01968265</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety tolerability ISIS-GCCRRx combination metformin versus placebo + metformin</brief_summary>
	<brief_title>Safety , Tolerability Efficacy ISIS-GCCRRx Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Male female , age 18 75 BMI great equal 25 HbA1c great equal 7.5 % less equal 10.5 % Type 2 Diabetes Mellitus stable dose oral metformin Agree conduct homebased ( fast ) blood glucose test direct Clinically significant abnormality medical history physical exam Show evidence uncorrected hypothyroidism hyperthyroidism hormone result History renal transplantation renal dialysis History liver disease History great 3 episode severe hypoglycemia within 6 month screen Use oral antidiabetic medication metformin within 3 month screen Use medication may affect plasma glucose level ( include systemic glucocorticoid ) , systemic steroid , corticosteroid , antiglucocorticoid therapy include mifepristone ketoconazole ( topical cream systemic ) , immunosuppressive medication , somatostatin analogue ACTH therapy within 3 month screen History diabetic ketoacidosis Current previous diagnosis Gilbert 's disease Any significant illness condition may interfere patient participate complete study Inability unwillingness comply protocol study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>T2DM</keyword>
</DOC>